DiNAMIQS opens production facility

DiNAMIQS AG, which is owned by Siegfried, has opened a new production plant for viral vectors in Schlieren in the Swiss canton of Zurich. This new facility will enable end-to-end manufacturing of viral vector gene therapies from development to filling under one roof.

DiNAMIQS AG has opened a cGMP (current Good Manufacturing Practices) plant for viral vectors covering an area of 2,500 square meters at its headquarters in the Bio-Technopark Schlieren-Zurich, as detailed in a company press release. The new facility will enable the "end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling", and is said to be the first of its kind in Switzerland, as the company, which is part of Siegfried AG from Zofingen in the canton of Aargau, explains in the press release.

The new facility complements the process development and quality control laboratories that were previously commissioned in 2024 and will reportedly strengthen Siegfried's position in the cell and gene therapy market, according to the press release. "Since acquiring the start-up in 2023, Siegfried's ambition has been to bring DiNAMIQS' capabilities to commercial scale and establish it as a leading CDMO in the cell and gene therapy space", as Marcel Imwinkelried, Chief Executive Officer at Siegfried, comments in relation to the activities as a contract development and manufacturing organization (CDMO), before adding: "With the opening of the new manufacturing facility and growing customer demand, we are well on track to achieving this goal".

With the commissioning of the new plant, DiNAMIQS has also entered into a strategic partnership with the Basel-based SEAL Therapeutics for the development and production of a gene therapy for muscular dystrophy.